Oricell Therapeutics (原启生物) is a Shanghai-based clinical-stage biopharmaceutical company developing cell-based immunotherapies for cancer, including GPC3-targeted CAR-T (Ori-C101) for advanced liver cancer and GPRC5D-targeted CAR-T (OriCAR-017) for relapsed/refractory multiple myeloma. - View it on GitHub